Science News
from research organizations

New phase II study supports potential of GS-9450 as new treatment option for steatohepatitis

Date:
April 16, 2010
Source:
European Association for the Study of the Liver
Summary:
Results from a multinational phase II study have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with nonalcoholic steatohepatitis (NASH -- the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.
Share:
       
FULL STORY

Results from a multinational phase II study presented at the International Liver Congress™ 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH -- the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.

GS-9450, a potent inhibitor of caspases-8, -9 and -1, the intra-cellular proteins that initiate programmed cell death (or cell suicide, also known as apoptosis) in damaged cells, is a potential new treatment option for patients with NASH -- a disease characterised by fat build-up in liver cells with subsequent inflammation resulting in accumulation of scar tissue (fibrosis), cirrhosis and eventual liver failure.

Professor Fabio Marra of the EASL scientific committee commented: "It is encouraging to see that GS-9450-associated reduction of apoptosis and cell damage seen in animal models has translated to a significant patient population, and seems to be consistent with a good tolerability profile in patients from a variety of countries. Further studies are needed to evaluate the action of this therapy on histology and to confirm the drug's efficacy and safety in larger patient populations."

In this double-blind, parallel-group study, patients (n=124, principally male, mean age 45 years, with Body Mass Index (BMI) of >30kg/m2) with biopsy-proven NASH were randomised to receive 1, 5, 10 or 40mg GS-9450 or placebo once daily for 4 weeks. After 4 weeks on treatment, patients in the 40mg treatment group experienced the greatest reduction in ALT and AST levels.

At week four, linear regression of ALT versus GS-9450 dose was highly significant (p<0.0001) with 35% achieving ALT levels within the normal range (7-56 U/L ) compared to 0% at study baseline, and 48% achieving normal levels of AST (5-40 U/L1) compared to 20% at baseline. Placebo treatment showed no meaningful change for ALT or AST.

Additionally, the on-treatment measure of cytokeratin-18 caspase cleavage fragments (proteins that act as markers for liver cell death) declined in the 10 and 40mg dose groups (median baseline and week four values respectively were 540 and 445 U/L in the 10mg group and 562 and 386 U/L in the 40mg group), although no dose-related response was seen.


Story Source:

The above post is reprinted from materials provided by European Association for the Study of the Liver. Note: Materials may be edited for content and length.


Cite This Page:

European Association for the Study of the Liver. "New phase II study supports potential of GS-9450 as new treatment option for steatohepatitis." ScienceDaily. ScienceDaily, 16 April 2010. <www.sciencedaily.com/releases/2010/04/100416144532.htm>.
European Association for the Study of the Liver. (2010, April 16). New phase II study supports potential of GS-9450 as new treatment option for steatohepatitis. ScienceDaily. Retrieved August 31, 2015 from www.sciencedaily.com/releases/2010/04/100416144532.htm
European Association for the Study of the Liver. "New phase II study supports potential of GS-9450 as new treatment option for steatohepatitis." ScienceDaily. www.sciencedaily.com/releases/2010/04/100416144532.htm (accessed August 31, 2015).

Share This Page: